ELI LILLY AND COMPAN

LLY
Delayed Quote. Delayed  - 11/25 04:10:00 pm
144.75USD -0.10%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Pharmaceuticals - NEC
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Number of employees : 33 625 people.
Sales per Business
2019
USD
(in Million)
%
Pharmaceutical Products 22,320100%
Sales per region
20182019
USD
(in Million)
%USD
(in Million)
%
United States 13,87556.5% 12,72357%
Europe 4,23117.2% 3,76516.9%
Other Foreign Countries 3,95616.1% 3,28414.7%
Japan 2,49410.2% 2,54811.4%
Managers
Name Title
David A. Ricks Chairman, President & Chief Executive Officer
Joshua L. Smiley Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Chief Information & Digital Officer, Senior VP
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Kathi P. Seifert Independent Director
Jon Erik Fyrwald Independent Director
Michael L. Eskew Independent Director
Ralph Alvarez Independent Director
Katherine Baicker Independent Director
Shareholders
Name Equities %
Lilly Endowment, Inc. 111,132,343 11.6%
Capital Research & Management Co. 109,033,091 11.4%
The Vanguard Group, Inc. 67,446,882 7.05%
The PNC Financial Services Group, Inc. 50,000,000 5.23%
PRIMECAP Management Co. 37,975,324 3.97%
SSgA Funds Management, Inc. 34,935,118 3.65%
Fidelity Management & Research Co. LLC 28,083,352 2.94%
Wellington Management Co. LLP 26,990,778 2.82%
BlackRock Fund Advisors 19,675,191 2.06%
State Farm Investment Management Corp. 18,619,725 1.95%
Company contact information
Eli Lilly & Co.
Lilly Corporate Center
Indianapolis, IN 46285

Phone : +1.317.276.2000
Web : http://www.lilly.com
Sector Pharmaceuticals - NEC
1st jan.Capi. (M$)
ELI LILLY AND COMPANY10.13%131 364
JOHNSON & JOHNSON-1.50%378 744
ROCHE HOLDING AG-4.28%281 946
PFIZER INC.-1.59%203 437
MERCK & CO., INC.-11.89%202 757
NOVARTIS AG-12.66%200 273
ABBVIE INC.17.42%183 539
NOVO NORDISK A/S6.76%152 574
BRISTOL-MYERS SQUIBB COMPANY-2.10%142 861
ASTRAZENECA PLC5.17%140 189
AMGEN INC.-8.61%128 345
SANOFI-6.04%125 712
GLAXOSMITHKLINE PLC-22.43%91 727
CHUGAI PHARMACEUTICAL CO., LTD.38.96%71 666
JIANGSU HENGRUI MEDICINE CO., LTD.18.09%69 882
DAIICHI SANKYO COMPANY, LIMITED53.61%67 733
BAYER AG-32.50%56 831
TAKEDA PHARMACEUTICAL COMPANY LIMITED-14.87%54 682
ASTELLAS PHARMA INC.-13.66%28 935
HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED33.40%26 840
CHANGCHUN HIGH & NEW TECHNOLOGY INDUSTRY (GROUP) INC.53.47%21 503
Brand Portfolio
ARMO BIOSCIENCES
ARMO BIOSCIENCES
CHEMGEN
CHEMGEN
ELI LILLY AND COMPANY
ELI LILLY AND COMPANY
IMCLONE SYSTEMS
IMCLONE SYSTEMS
LOXO ONCOLOGY
LOXO ONCOLOGY
PHARMASERVE-LILLY
PHARMASERVE-LILLY
» More brands of Eli Lilly And Company